妊娠相关非典型溶血性尿毒症综合征的系统综述
该系统综述检索截至2018年3月,纳入48篇报告共60例妊娠相关aHUS患者(66次妊娠)。首发病例多在产后(94%)、剖宫产术后(70%)诊断,常 preceded by 产科并发症。接受依库珠单抗治疗者疾病缓解率显著高于未接受者(88% vs 57%,P=.02)。
要点
- 妊娠相关aHUS首发病例多在产后诊断(94%),常发生于剖宫产术后(70%)。
- 诊断基于微血管病性溶血、血小板减少和肾功能衰竭三联征。
- 依库珠单抗治疗者疾病缓解率88%,未治疗者57%(P=.02)。
核心结论
- 妊娠相关aHUS通常表现为产后发病,常发生于妊娠并发症之后,依库珠单抗对实现疾病缓解有效。
研究设计与样本
- 系统综述,检索PubMed、MEDLINE、Cochrane Library、ClinicalTrials.gov、Web of Science、EMBASE和Google Scholar从建库至2018年3月。
- 纳入48篇报告描述60例妊娠相关aHUS独特病例,共66次妊娠;其中12例为已知aHUS女性的妊娠,54例为首发妊娠相关aHUS。
主要发现
- 已知aHUS女性,尤其是基线肌酐≥1.5 mg/dL者,不良妊娠结局发生率高。
- 首发病例诊断最常见于产后(94%)、剖宫产术后(70%)、未产女性(58%)。
- 常见的前驱产科并发症包括胎儿死亡、子痫前期和出血。
- 诊断通常基于微血管病性溶血、血小板减少和肾功能衰竭三联征临床作出,辅助检查包括肾活检、补体基因检测和ADAMTS13检测。
- 治疗方式包括糖皮质激素、血浆置换、透析和依库珠单抗;接受依库珠单抗治疗的首发病例疾病缓解率高于未接受者(88% vs 57%,P=.02)。
关键数值与推荐
- aHUS诊断特征为溶血、血小板减少和肾功能衰竭,并与典型腹泻相关溶血性尿毒症综合征相区分。
- 排除标准包括无法获取个体数据、诊断不明确或更可能存在替代病因(如血栓性血小板减少性紫癜或产志贺毒素大肠埃希菌)。
- 首发病例中,接受依库珠单抗治疗者疾病缓解率88%,未接受者57%(P=.02)。
临床怎么用
- 对于产后出现微血管病性溶血、血小板减少和肾功能衰竭的妇女,应考虑妊娠相关aHUS。
- 依库珠单抗可用于妊娠相关aHUS以实现疾病缓解。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate disease presentation, diagnosis, treatment, and clinical outcomes in pregnancy-associated atypical hemolytic uremic syndrome (aHUS). DATA SOURCES: We searched PubMed, MEDLINE, Cochrane Library, ClinicalTrials.gov, Web of Science, EMBASE and Google Scholar, from inception until March 2018. METHODS OF STUDY SELECTION: We included English-language articles describing aHUS in pregnancy or postpartum. The diagnosis of aHUS was characterized by hemolysis, thrombocytopenia, and renal failure and was distinguished from typical diarrhea-associated hemolytic uremic syndrome. Patients were excluded if individual data could not be obtained, the diagnosis was unclear, or an alternative etiology was more likely, such as thrombotic thrombocytopenic purpura or Shiga toxin-producing Escherichia coli. Reports were appraised by two reviewers, with disagreements adjudicated by a third reviewer. TABULATION, INTEGRATION, AND RESULTS: The search identified 796 articles. After review of titles, abstracts, and full text, we identified 48 reports describing 60 unique cases of pregnancy-associated aHUS, with 66 pregnancies. Twelve cases involved pregnancy in women with known aHUS, and 54 cases involved first-episode pregnancy-associated aHUS. Women with known aHUS, particularly those with baseline creatinine at or above 1.5 mg/dL, had a high rate of adverse pregnancy outcomes. For first-episode pregnancy-associated aHUS, diagnosis most often occurred postpartum (94%), after a cesarean delivery (70%), in nulliparous women (58%). Preceding obstetric complications were common and included fetal death, preeclampsia, and hemorrhage. Diagnosis was usually made clinically, based on the triad of microangiopathic hemolysis, thrombocytopenia, and renal failure. Additional testing included renal biopsy, complement genetic testing, and ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) testing. Treatment modalities included corticosteroids, plasma exchange, dialysis, and eculizumab. More women with first-episode pregnancy-associated aHUS achieved disease remission when treated with eculizumab, compared with those not treated with eculizumab (88% vs 57%, P=.02). CONCLUSION: Pregnancy-associated aHUS usually presents in the postpartum period, often after a pregnancy complication, and eculizumab is effective for achieving disease remission. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42019129266.
引用
- Gupta M, Govindappagari S, Burwick RM, et al. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Systematic Review. Obstet Gynecol. 2020. PMID: 31809447. doi:10.1097/AOG.0000000000003554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。